Friday, January 3, 2014
Testosterone Therapy Linked With Adverse CVD Events
DENVER, CO — The use of testosterone therapy in men is associated with an increased risk of death, MI, or ischemic stroke, according to the results of a new study[1]. The increased risk, which was about 30% higher in men treated with testosterone than in those who did not receive it, was observed in a cohort of Veterans Affairs (VA) patients with multiple comorbidities undergoing coronary angiography.
"We found an association; it's not causal, given the observational nature of the study," senior investigator Dr Michael Ho (Veterans Affairs Eastern Colorado Health Care System, Denver) told heartwire . "It does provide some evidence that testosterone therapy may be associated with some increased risk of adverse cardiovascular outcomes. For patients who are starting therapy or who are currently on therapy, this might warrant a discussion with their physicians about the potential benefits of the therapy vs the potential risk. I think that decision should be individualized for each patient."
Read the full Medscape report
Labels:
Testosterone
Tuesday, October 1, 2013
PSA Screening Does More Harm Than Good, Says New Analysis
Medscape Medical News
AMSTERDAM — To the ongoing debate over whether routine screening for prostate cancer reduces prostate cancer mortality comes a new analysis that suggests that it does more harm than good.
The total harms that men experience in terms of impotence, incontinence, and other side effects from prostate cancer treatment can severely affect their quality of life, lead author Mathieu Boniol, MD, said here at the European Cancer Conference 2013 (ECCO-ESMO-ESTRO).
Dr. Boniol and colleagues conducted a systematic review of the literature for data on results of prostate-specific antigen (PSA) testing, biopsy rates, and mortality/associated side effects from radical prostatectomy, as well as hospitalization rates associated with biopsy. They also used data from the European Randomized Study of Screening for Prostate Cancer, which is the study showing the most favorable outcomes for PSA screening.
Read the full Medscape Medical News report
(free sign-up may be required)
Roxanne Nelson
Sep 29, 2013AMSTERDAM — To the ongoing debate over whether routine screening for prostate cancer reduces prostate cancer mortality comes a new analysis that suggests that it does more harm than good.
The total harms that men experience in terms of impotence, incontinence, and other side effects from prostate cancer treatment can severely affect their quality of life, lead author Mathieu Boniol, MD, said here at the European Cancer Conference 2013 (ECCO-ESMO-ESTRO).
Dr. Boniol and colleagues conducted a systematic review of the literature for data on results of prostate-specific antigen (PSA) testing, biopsy rates, and mortality/associated side effects from radical prostatectomy, as well as hospitalization rates associated with biopsy. They also used data from the European Randomized Study of Screening for Prostate Cancer, which is the study showing the most favorable outcomes for PSA screening.
Read the full Medscape Medical News report
(free sign-up may be required)
Labels:
Prostate Cancer,
Prostate Screening,
PSA
Testosterone Therapy: Scant Evidence of Benefit in CVD Risk
Medscape Medical News
Although there is some evidence that low endogenous testosterone levels may be linked to cardiovascular risk, a review of the last 43 years of literature finds scant definitive evidence that testosterone supplementation affects that risk.
Johannes B. Ruige, MD, PhD, from the Department of Endocrinology, Ghent University Hospital, Belgium, and colleagues. report their findings in an article published online September 24 in the Journal of Clinical Endocrinology & Metabolism.
Read the full Mescape Medical News report
(free sign-up may be required)
Steven Fox
Sep 25, 2013Although there is some evidence that low endogenous testosterone levels may be linked to cardiovascular risk, a review of the last 43 years of literature finds scant definitive evidence that testosterone supplementation affects that risk.
Johannes B. Ruige, MD, PhD, from the Department of Endocrinology, Ghent University Hospital, Belgium, and colleagues. report their findings in an article published online September 24 in the Journal of Clinical Endocrinology & Metabolism.
Read the full Mescape Medical News report
(free sign-up may be required)
Labels:
Testosterone
Friday, September 20, 2013
Healthy Habits Linked to Longer Telomeres in Prostate Cancer
Medscape Medical News (Oncology)
Neil Osterwell
Sept. 16, 2013
A comprehensive lifestyle intervention might help prostate cancer patients live to be longer in the tooth and in the telomere, suggest results of a very small pilot study reported online in The Lancet Oncology.
Among 35 men with biopsy-proven, low-risk prostate cancer who opted for active surveillance, a comprehensive lifestyle intervention including diet, activity, stress management, and support was associated with lengthening of telomeres over 5 years compared with a loss of telomere length among controls, report Dean Ornish MD, director of the Preventive Medicine Research Institute, in Sausalito, California, and colleagues.
Read the full Medscape report
(free sign-up may be required)
Neil Osterwell
Sept. 16, 2013
A comprehensive lifestyle intervention might help prostate cancer patients live to be longer in the tooth and in the telomere, suggest results of a very small pilot study reported online in The Lancet Oncology.
Among 35 men with biopsy-proven, low-risk prostate cancer who opted for active surveillance, a comprehensive lifestyle intervention including diet, activity, stress management, and support was associated with lengthening of telomeres over 5 years compared with a loss of telomere length among controls, report Dean Ornish MD, director of the Preventive Medicine Research Institute, in Sausalito, California, and colleagues.
Read the full Medscape report
(free sign-up may be required)
Labels:
Prostate Cancer
FDA OKs New Device to Treat BPH
Medscape Medical News
Mark Crane
Sept. 13, 2013
The US Food and Drug Administration (FDA) today authorized the marketing of the UroLift system, the first permanent implant to relieve low or blocked urine flow in men aged 50 years and older with an enlarged prostate.
The UroLift system relieves the urine flow by pulling back the prostate tissue that is pressing on the urethra.
"The UroLift provides a less invasive alternative to treating [benign prostatic hyperplasia] than surgery," Christy Foreman, director of the Office of Device Evaluation at the FDA's Center for Devices and Radiological Health, said in a release. "This device also may offer relief to men who cannot tolerate available drug therapies."
Read the full Medscape report
(Free sign-up may be required)
Mark Crane
Sept. 13, 2013
The US Food and Drug Administration (FDA) today authorized the marketing of the UroLift system, the first permanent implant to relieve low or blocked urine flow in men aged 50 years and older with an enlarged prostate.
The UroLift system relieves the urine flow by pulling back the prostate tissue that is pressing on the urethra.
"The UroLift provides a less invasive alternative to treating [benign prostatic hyperplasia] than surgery," Christy Foreman, director of the Office of Device Evaluation at the FDA's Center for Devices and Radiological Health, said in a release. "This device also may offer relief to men who cannot tolerate available drug therapies."
Read the full Medscape report
(Free sign-up may be required)
Complications of Robotic Surgery Underreported
Medscape Medical News
Robert Lowes
Sept 05, 2013
More injuries and deaths are linked to da Vinci robotic surgery than meet the eye, according to a new study published online August 27 in the Journal for Healthcare Quality.
As a result, "we're not learning from our performance," study coauthor Martin Makary, MD, MPH, told Medscape Medical News.
Between January 1, 2000, and August 1, 2012, the US Food and Drug Administration (FDA) received 245 adverse event (AE) reports related to the controversial da Vinci robotic surgical system, made by Intuitive Surgical. Scouring federal court records and media accounts, Dr. Makary and colleagues found 5 more cases that were never reported. They also discovered that 3 reported cases were problematic. One was submitted 930 days after the surgery, and another 292 days after. The latter case, as well as a third dubious one, was submitted to the FDA only after a media report of the patient's death appeared.
Read the full Medscape report
Robert Lowes
Sept 05, 2013
More injuries and deaths are linked to da Vinci robotic surgery than meet the eye, according to a new study published online August 27 in the Journal for Healthcare Quality.
As a result, "we're not learning from our performance," study coauthor Martin Makary, MD, MPH, told Medscape Medical News.
Between January 1, 2000, and August 1, 2012, the US Food and Drug Administration (FDA) received 245 adverse event (AE) reports related to the controversial da Vinci robotic surgical system, made by Intuitive Surgical. Scouring federal court records and media accounts, Dr. Makary and colleagues found 5 more cases that were never reported. They also discovered that 3 reported cases were problematic. One was submitted 930 days after the surgery, and another 292 days after. The latter case, as well as a third dubious one, was submitted to the FDA only after a media report of the patient's death appeared.
Read the full Medscape report
Labels:
Prostate,
Prostate Cancer
Wednesday, August 28, 2013
Night Work May Shift PSA Level Higher
Medscape Oncology -
Men engaged in shift work, including working at night or on a rotating schedule, had an increased likelihood of having an elevated prostate-specific antigen (PSA) value, according to new American research.
Specifically, there was a statistically significant association between current shift work and an elevated PSA of 4.0 ng/mL or greater. The study is based on data from the National Health and Nutrition Examination Survey (NHANES).
Read the full Medscape Medical News report here
Nick Mulcahy
Aug 22, 2013Men engaged in shift work, including working at night or on a rotating schedule, had an increased likelihood of having an elevated prostate-specific antigen (PSA) value, according to new American research.
Specifically, there was a statistically significant association between current shift work and an elevated PSA of 4.0 ng/mL or greater. The study is based on data from the National Health and Nutrition Examination Survey (NHANES).
Read the full Medscape Medical News report here
Labels:
Prostate Cancer,
PSA
Subscribe to:
Posts (Atom)